Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma

被引：80

作者：

Ludwig, Heinz ^{[1
]}

Drach, Johannes ^{[2
]}

Graf, Helmut ^{[3
]}

Lang, Alois ^{[4
]}

Meran, Johannes Gobertus ^{[5
]}

机构：

[1] Wilhelminenspital Stadt Wien, Dept Med 1, Ctr Oncol & Hematol, Montleartstr 37, A-1170 Vienna, Austria

[2] Univ Hosp, Dept Internal Med 1, Div Oncol, Vienna, Austria

[3] Krankenanstalt Rudolfstiftung Wien, Internal Dept 3, Vienna, Austria

[4] LKH Feldkirch, Dept Internal Med, Feldkirch, Austria

[5] Krankenhaus Barmherzigen Brueder, Vienna, Austria

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 10期

关键词：

acute paraprotein-induced renal failure; multiple myeloma; nephrotoxic light chains; bortezomib; hemodialysis;

D O I：

10.3324/haematol.11463

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Paraprotein induced renal failure is a frequent complication of multiple myeloma and is associated with poor survival. Previously, reversal of renal function has been hampered by the lack of fast acting and highly effective myeloma therapy and most patients remained or became dependent on hemodialysis. Here we show reversal of acute paraprotein-induced renal failure by bortezomib-based therapy in 5 out of 8 patients. Improvement of renal function was preceded by a significant reduction in paraprotein concentration in all patients, with improvement in renal function.

引用

页码：1411 / 1414

页数：4

共 50 条

[1] Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
Roussou, Maria
Kastritis, Efstathios
Migkou, Magdalini
Psimenou, Erasmia
Grapsa, Irini
Matsouka, Charis
Barmparousi, Despina
Terpos, Evangelos
Dimopoulos, Meletios Athanasios
[J]. LEUKEMIA & LYMPHOMA, 2008, 49 (05) : 890 - 895
[2] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment
Bao, Li
Lu, Jin
Wang, Shihua
Huang, Xiaojun
[J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6200 - 6209
[3] REVERSIBILITY OF RENAL FAILURE IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS: A SINGLE CENTRE EXPERIENCE
Stefanikova, Z.
Roziakova, L.
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 593 - 593
[4] BORTEZOMIB-BASED THERAPY IN FRAIL MULTIPLE MYELOMA PATIENTS
Antonioli, E.
Staderini, M.
Nozzoli, C.
Bacchiarri, F.
Barone, F.
Grieco, P.
Coltro, G.
Guarrera, A.
Messeri, M.
Bosi, A.
[J]. HAEMATOLOGICA, 2017, 102 : 132 - 132
[5] Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure
Helen Gharwan
Cristina I. Truica
[J]. Medical Oncology, 2012, 29 : 1197 - 1201
[6] Voriconazole Increase the Risk of PN in Multiple Myeloma Patients Treated with Bortezomib-Based Chemotherapy
Xu, Yan
Deng, Shuhui
An, Gang
Li, Zengjun
Qin, Xiaoqi
Sui, Weiwei
Feng, Xiaoyan
Zou, Dehui
Qiu, Lugui
[J]. BLOOD, 2015, 126 (23)
[7] Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure
Gharwan, Helen
Truica, Cristina I.
[J]. MEDICAL ONCOLOGY, 2012, 29 (02) : 1197 - 1201
[8] Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity
Heitner, Stephen B.
Minnier, Jessica
Naher, Aynun
Van Woerkom, Ryan C.
Ritts, Alexandra
Ferencik, Maros
Broberg, Craig
Medvedova, Eva
Silbermann, Rebecca
Scott, Emma C.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (12): : 796 - 802
[9] Bortezomib-based chemotherapy for patients with multipe myeloma:a single center experience
梁赜隐
[J]. China Medical Abstracts (Internal Medicine), 2014, 31 (02) : 123 - 124
[10] Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure
Malani, Ashok Kumar
Gupta, Vicram
Rangineni, Raj
[J]. ACTA HAEMATOLOGICA, 2006, 116 (04) : 255 - 258

← 1 2 3 4 5 →